Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 49

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 49
---
 is $4,028,889 as of March 31, 2025. A delisting of our common stock from Nasdaq may materially
impair our stockholders’ ability to buy and sell our common stock and could have an adverse effect on the market price of, and the
efficiency of the trading market for, our common stock. In addition, the delisting of our common stock could significantly impair our
ability to raise capital. Also, our Board may determine that the cost of maintaining our listing on a national securities exchange
outweighs the benefits of such listing. An active trading market for our shares may never develop or be sustained.

<div align='center'>23</div>

Any delisting determination by Nasdaq could seriously
decrease or eliminate the value of an investment in our common stock and other securities linked to our common stock. While a listing
on an over-the-counter exchange could maintain some degree of a market in our common stock, we could face substantial material adverse
consequences, including, but not limited to, the following: limited availability for market quotations for our common stock; reduced liquidity
with respect to and decreased trading prices of our common stock; a determination that shares of our common stock are “penny stock”
under the SEC rules, subjecting brokers trading our common stock to more stringent rules on disclosure and the class of investors to which
the broker may sell the common stock; limited news and analyst coverage for our Company, in part due to the “penny stock”
rules; decreased ability to issue additional securities or obtain additional financing in the future; and potential breaches under or
terminations of our agreements with current or prospective large stockholders, strategic investors and banks. The perception among investors
that we are at heightened risk of delisting could also negatively affect the market price of our securities and trading volume of our
common stock.

A possible “short squeeze” due to a sudden increase in demand of our common stock that largely exceeds supply may lead to price volatility in our common stock.

Investors may purchase our common stock to hedge
existing exposure in our common stock or to speculate on the price of our common stock. Speculation on the price of our common stock may
involve long and short exposures. To the extent aggregate short exposure exceeds the number of shares of our common stock available for
purchase in the open market, investors with short exposure may have to pay a premium to repurchase our common stock for delivery to lenders
of our common stock. Those repurchases may in